AnnualReports.com – the leading provider of online annual reports to individual and institutional investors.

Optimer Pharmaceuticals, Inc.


Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea.

View Online Reports: Order Free Hardcopy You can request a free hardcopy of this report mailed to you by clicking the button below.
Add Annual Report

No investor fact sheets added yet
No responsibility reports added yet

Browse Reports